Vorinostat-like molecules as structural, stereochemical, and pharmacological tools

ACS Medicinal Chemistry Letters

Volumn 1, Issue 2, 2010, Pages 70-74

  Hanessian, Stephen ^a   Auzzas, Luciana ^a,b   Larsson, Andreas ^a,c   Zhang, Jianbin ^a   Giannini, Giuseppe ^d   Gallo, Grazia ^d   Ciacci, Andrea ^d   Cabri, Walter ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CNR   (Italy)

^c UMEÅ UNIVERSITY   (Sweden)

^d Sigma Tau SpA   (Italy)

Author keywords

absorption and metabolism; class IIa specific profile; HDAC promiscuous inhibitors; HDAC1 11 profile; SAHA analogues

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; CAFFEINE; CIMETIDINE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; VINBLASTINE; VORINOSTAT;

ARTICLE; DRUG ABSORPTION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 77956635368     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100028g     Document Type: Article

References (34)

1. Zhang, L., Fang, H., and Xu, W. Strategies in Developing Promising Histone Deacetylase Inhibitors. Med. Res. Rev. 2009, DOI: 10.1002/med.20169.
2. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone Deacetylase Inhibitors: From Bench to Clinic J. Med. Chem. 2008, 51, 1505-1529
3. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer Activities of Histone Deacetylase Inhibitors Nat. Rev. Drug Discovery 2006, 5, 769-784
4. Minucci, S.; Pelicci, P. G. Histone Deacetylase Inhibitors and the Promise of Epigenetic (and More) Treatments for Cancer Nat. Rev. Cancer 2006, 6, 38-51
5. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC Family: What Are the Cancer Relevant Targets? Cancer Lett. 2009, 277, 8-21
6. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Rithchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M. Determination of the Class and Isoform Selectivity of Small-Molecule Histone Deacetylase Inhibitors Biochem. J. 2008, 409, 581-589
7. Bieliauskas, A. V.; Pflum, M. K. H. Isoform-Selective Histone Deacetylase Inhibitors Chem. Soc. Rev. 2008, 37, 1402-1413
8. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfí, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate Binding to Histone Deacetylase as Shown by the Crystal Structure of the HDAC8-Substrate Complex. EMBO Rep. 2007, 8, 879 ? 884 and references therein.
9. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.; Maglathin, R. L.; McLean, T. H.; Bochkarev, A.; Plotnikov, A. N.; Vedadi, M.; Arrowsmith, C. H. J. Human HDAC7 Harbors a Class IIa Histone Deacetylase-Specific Zinc Binding Motif and Cryptic Deacetylase Activity J. Biol. Chem. 2008, 283, 11355-11363
10. Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkühler, C.; Gallinari, P.; Carf, A. Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain. J. Biol. Chem. 2008, 283, 26694 ? 26704 and references therein.
11. http://www.actrec.gov.in/histone/infobase.htm.
12. Hu, F.; Chou, C. J.; Gottesfeld, J. M. Design and Synthesis of Novel Hybrid Benzamide-Peptide Histone Deacetylase Inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 3928-3931
13. 3β-Tetrapeptides. J. Med. Chem. 2009, 52, 7836 ? 7846 and references therein.
14. Bowers, A. A.; Greshock, T. J.; West, N.; Estiu, G.; Schreiber, S. L.; Wiest, O.; Williams, R. M.; Bradner, J. E. Synthesis and Conformation-Activity Relationships of the Peptide Isosteres of FK228 and Largazole J. Am. Chem. Soc. 2009, 131, 2900-2905
15. Blackwell, L.; Norris, J.; Suto, C. M.; Janzen, W. P. The Use of Diversity Profiling to Characterize Chemical Modulators of the Histone Deacetylases Life Sci. 2008, 82, 1050-1058
16. Lahm, A.; Paolini, M.; Pallaoro, M.; Nardi, M. C.; Jones, P.; Nedderman, P.; Sambucini, S.; Bottomley, M. J.; Lo Surdo, P.; Carfí, A.; Koch, U.; De Francesco, R.; Steinkühler, C.; Gallinari, P. Unraveling the Hidden Catalytic Activity of Vertebrate Class IIa Histone Deacetylases Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 17335-17340
17. Bradner, J. E.; West, N.; Grachan, M. L.; Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R. Chemical Phylogenetics of Histone Deacetylases. Nat. Chem. Biol. 2010, 6, 238 ? 243 and references therein.
18. For a recent example of HDAC profiling in the development of a potent inhibitor, see the following: Arts, J.; King, P.; Mariën, A.; Floren, W.; Beliën, A.; Janssen, L.; Pilatte, I.; Roux, B.; Decrane, L.; Gilissen, R.; Hickson, I.; Vreys, V.; Cox, E.; Bol, K.; Talloen, W.; Goris, I.; Andries, L.; Du Jardin, M.; Janicot, M.; Page, M.; van Emelen, K.; Angibaud, P. JNJ-26481585, a Novel 'Second Generation' Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity Clin. Cancer Res. 2009, 15, 6841-6851 For further selected examples, see the Supporting Information.
19. Marks, P. A.; Breslow, R. Dimethyl Sulfoxide to Vorinostat: Development of This Histone Deacetylase Inhibitor as an Anticancer Drug Nat. Biotechnol. 2007, 25, 84-90
20. Hanessian, S.; Auzzas, L.; Giannini, G.; Marzi, M.; Cabri, W.; Barbarino, M.; Vesci, L.; Pisano, C. ?-Alkoxy Analogues of SAHA (Vorinostat) as Inhibitors of HDAC: A Study of Chain-Length and Stereochemical Dependence Bioorg. Med. Chem. Lett. 2007, 17, 6261-6265
21. Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. A General Model for Selectivity in Olefin Cross Metathesis J. Am. Chem. Soc. 2003, 125, 11360-11370
22. Dixon, D. J.; Ley, S. V.; Tate, E. W. A Total Synthesis of (+)-Goniodiol Using an Anomeric Oxygen-to-Carbon Rearrangement J. Chem. Soc., Perkin Trans. 1 1998, 3125-3126
23. Rai, A. N.; Basu, A. An Efficient Method for para-Methoxybenzyl Ether Formation with Lanthanum Triflate Tetrahedron Lett. 2003, 44, 2267-2269
24. Li, H.; Jiang, X.; Ye, Y.-H.; Fan, C.; Romoff, T.; Goodman, M. 3-(Diethoxyphosphoryloxy)-1,2,3- benzotriazin-4(3H)-one (DEPBT): A New Coupling Reagent with Remarkable Resistance to Racemization Org. Lett. 1999, 1, 91-93
25. (S) isomers of simple ?-substitute amide derivatives of SAHA have been reported as potent HDAC inhibitors, although any relationship about chirality was not described; see the following: Richon, V.; Marks, P. A.; Rifkind, R. A.; Breslow, R.; Belvedere, S.; Gershell, L.; Miller, T. A. Novel Class of Cytodifferentiating Agents and Histone Deacetylase Inhibitors, and Methods of Use Thereof. WO0118171-A2, 2001.
26. Mori, K.; Koseki, K. Synthesis of Trichostatin A, a Potent Differentiation Inducer of Friend Leukemic Cells, and Its Antipode Tetrahedron 1988, 44, 6013-6020
27. Remiszewski, S. W. The Discovery of NVP-LAQ824: From Concept to Clinic Curr. Med. Chem. 2003, 10, 2393-2402
28. High-resolution HDAC8/MS-344 and HDAC7/TSA complexes were used (PDB codes: 1T67 and 3C10, respectively). These are better resolved than the cocrystals of SAHA with the same HDACs (1T69 and 3COZ, respectively). In addition, a water molecule is present only in 1T67, which is thought to be responsible for the stabilization of MS-344 through its amide bond. See ref 8.
29. Calculated with LPC software. This is freely accessible at http://bip.weizmann.ac.il/oca-bin/lpccsu. Sobolev, V.; Sorokine, A.; Prilusky, J.; Abola, E. E.; Edelman, M. Automated Analysis of Interatomic Contacts in Proteins. Bioinformatics 1999, 15, 327 ? 332.
30. Davis, A. M.; Teague, S. J. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis Angew. Chem., Int. Ed. 1999, 38, 736-749
31. Ortore, G.; Di Colo, F.; Martinelli, A. Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities J. Chem. Inf. Model. 2009, 49, 2774-2785
32. Gres, M.-C.; Julian, B.; Bourrié, M.; Meunier, V.; Roques, C.; Berger, M.; Boulenc, X.; Berger, Y.; Fabre, G. Correlation Between Oral Drug Absorption in Humans, and Apparent Drug Permeability in TC-7 Cells, a Human Epithelial Intestinal Cell Line: Comparison with the Parental Caco-2 Cell Line Pharm. Res. 1998, 15, 726-733
33. Li, P. E.; Lu, C.; Brent, J. A.; Pham, C.; Fackett, A.; Ruegg, C. E.; Silber, P. M. Cryopreserved Human Hepatocytes: Characterization of Drug-Metabolizing Enzyme Activities and Applications in Higher Throughput Screening Assays for Hepatotoxicity, Metabolic Sability, and Drug-Dug Interaction Potential Chem.-Biol. Interact. 1999, 121, 17-35
34. For a comparison of pharmacokinetics of Vorinostat with certain mercaptoacetamides, see the following: Konsoula, R.; Jung, M. Int. J. Pharm. 2008, 361, 19 ? 25.